Skip to main content
. 2021 Jan 12;14(3):101014. doi: 10.1016/j.tranon.2021.101014

Table 1.

Patient demographics and baseline disease characteristics of the enrolled patients in the clinical trial (as previously reported in [10]).

Variable No. of Patients (%)
Age (years); Median (range) 61 (37–76)
Cutaneous primary 21 (70)
Unknown primary 8 (27)
Mucosal 1 (3)
Gender Female 12 (40)
Male 18 (60)
Performance
Status
0 16 (53)
1 14 (47)
BRAF mutation (+) 8 (27)
BRAF wild type 13 (43)
Unknown 9 (30)
Recurrent disease after prior surgery 15 (50)
Presence of in-transit metastases 16 (53)
Prior adjuvant HDI 5 (17)
Estimated risk Stage

IIIB 3 (10)
IIIC 25 (83)
*IV (Not eligible) 2 (7)

HDI: High-dose interferon-a; ECOG: Eastern Cooperative Oncology Group.